Company Overview
Snapshot
Founded in September 2022 by Gil Senesh, BeCapio operates with 1–10 employees. The company has secured funding across one round from two investors, with The Trendlines Group identified as a lead investor. In November 2022, BeCapio received its initial funding, marking a key milestone in its development of non-invasive therapeutic solutions.
Business overview
BeCapio is a Health Tech & Life Sciences company focused on developing digital therapeutics for patients. The company aims to empower individuals dealing with Fecal Incontinence Disorder by providing a discrete, non-invasive, multi-modal therapy. Its core product is designed to help users regain control and maintain everyday activities, operating within the Digital Healthcare sector and targeting patients directly.
Log in to access full profile ›Company Intelligence Q&A
- When was BeCapio founded?
- BeCapio was founded in September 2022 by Gil Senesh.
- What is BeCapio's primary focus?
- BeCapio focuses on providing a discrete, non-invasive, multi-modal therapy to help people dealing with Fecal Incontinence Disorder regain control and maintain everyday activities.
- Which investors participated in BeCapio's funding round?
- In November 2022, BeCapio received funding from The Trendlines Group and Israel Innovation Authority.
- What is the employee count for BeCapio?
- BeCapio currently operates with 1–10 employees.
- What stage is BeCapio's product development in?
- BeCapio's product is currently in the R&D stage, working towards developing a non-invasive, multi-modal therapy for fecal incontinence.